Iktos announces an additional collaboration agreement in AI for new drug design with Merck KGaA, Darmstadt, Germany, a leading science and technology company. In this new collaboration, Iktos’s de novo generative design technology will be used in a structure-enabled context to facilitate the rapid and cost-effective design of an undisclosed Merck KGaA, Darmstadt, Germany drug discovery program. Follow the link for the full press release.